OBI Pharma Inc (4174):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:OBI Pharma Inc (4174) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8254
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
OBI Pharma Inc (OBI Pharma) is a biopharmaceutical company that develops therapies for the treatment of cancer and infectious diseases. The company’s products include adagloxad simolenin, an active immunotherapy which is intended for the treatment of metastatic breast cancer; and OBI-833, a cancer vaccine for epithelial cancers other than breast and ovarian cancer. It also develops active immunotherapies intended for the treatment of various lung, prostate, pancreatic, stomach and ovarian cancers. OBI Pharma develops its pipeline products through its carbohydrate synthesis discovery platform. The company has collaboration with research institutes including cancer centers to enhance its pipeline products. It operates in the US, Taiwan and China. OBI Pharma is headquartered in Taipei, Taiwan.

OBI Pharma Inc (4174) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OBI Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
OBI Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 9
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
OBI Pharma to Acquire TH-3424 from Threshold Pharma 11
Venture Financing 12
Optimer Biotech Raises US$18.3 Million In Financing 12
Partnerships 13
Merck Enters into Agreement with OBI Pharma 13
Licensing Agreements 14
OBI Pharma Enters into Licensing Agreement with Abzena 14
Equity Offering 15
OBI Pharma Raises USD51 Million through Issue of Shares 15
Acquisition 16
OBI Pharma to Acquire 70% Stake in AP Biosciences from AbProtix 16
Taiwanese Investor Consortium Completes First Tranche Acquisition Of Remaining 43.5% Stake In Optimer Biotech 17
Optimer Pharma Acquires 0.7% Stake In Optimer Biotech For US$0.5 Million 19
Optimer Pharma Sells Minority Stake In Optimer Biotech 20
OBI Pharma Inc – Key Employees 22
OBI Pharma Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Product News 24
01/17/2018: OBI Pharma Announces FDA Clearance Of IND Application For A Phase 1 Study Of A Monoclonal Antibody Cancer Immunotherapy (OBI-888) 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
OBI Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OBI Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OBI Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8
OBI Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 9
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
OBI Pharma to Acquire TH-3424 from Threshold Pharma 11
Optimer Biotech Raises US$18.3 Million In Financing 12
Merck Enters into Agreement with OBI Pharma 13
OBI Pharma Enters into Licensing Agreement with Abzena 14
OBI Pharma Raises USD51 Million through Issue of Shares 15
OBI Pharma to Acquire 70% Stake in AP Biosciences from AbProtix 16
Taiwanese Investor Consortium Completes First Tranche Acquisition Of Remaining 43.5% Stake In Optimer Biotech 17
Optimer Pharma Acquires 0.7% Stake In Optimer Biotech For US$0.5 Million 19
Optimer Pharma Sells Minority Stake In Optimer Biotech 20
OBI Pharma Inc, Key Competitors 21
OBI Pharma Inc, Key Employees 22
OBI Pharma Inc, Other Locations 23
OBI Pharma Inc, Subsidiaries 23

List of Figures
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OBI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
OBI Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[OBI Pharma Inc (4174):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • AF Gruppen ASA (AFG):企業の財務・戦略的SWOT分析
    AF Gruppen ASA (AFG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Red Hat Inc:企業の戦略的SWOT分析
    Red Hat Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • AKB Rosbank:企業の戦略・SWOT・財務情報
    AKB Rosbank - Strategy, SWOT and Corporate Finance Report Summary AKB Rosbank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Amplyx Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Amplyx Pharmaceuticals Inc (Amplyx) is a developer of antifungal medicines. The company develops antifungal agents for the treatment of life-threatening invasive fungal infections due to candidia, aspergillus and rare molds. It also develops small molecule therapy APX001, which is in clinica …
  • Nokia Corporation:戦略・SWOT・企業財務分析
    Nokia Corporation - Strategy, SWOT and Corporate Finance Report Summary Nokia Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Steel Authority Of India Ltd:企業の戦略・SWOT・財務分析
    Steel Authority Of India Ltd - Strategy, SWOT and Corporate Finance Report Summary Steel Authority Of India Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Active Implants LLC:医療機器:M&Aディール及び事業提携情報
    Summary Active Implants LLC (Active Implants), formerly Active Implants Corp is a medical equipment provider that develops orthopedic equipment. The company develops and commercializes polymer orthopedic implant solutions which include tribofit hip system, tribofit instrumentation equipment, NuSurfa …
  • TETRA Technologies Inc (TTI):企業の財務・戦略的SWOT分析
    Summary TETRA Technologies Inc (TETRA) is an oil and gas company that offers completion fluids and associated products and services. The company’s services comprise compression services, fluid, filtration and tools services, offshore services, production testing, rig cooling services, technology cen …
  • Merck KGaA (MRK):医療機器:M&Aディール及び事業提携情報
    Summary Merck KGaA (Merck), a subsidiary of E. Merck KG, is a pharmaceutical and chemical company. It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis, and infertility and over-the-counter products for colds and pain; and develops liquid crystal mixtures, O …
  • Essar Power Ltd:企業の戦略的SWOT分析
    Essar Power Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Emzor Pharmaceutical Industries Ltd:企業の戦略的SWOT分析
    Emzor Pharmaceutical Industries Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • DMC Global Inc (BOOM):企業の財務・戦略的SWOT分析
    Summary DMC Global Inc (DMC), formerly Dynamic Materials Corp is an industrial equipment and machinery company. It manufactures, distributes, and markets explosion welded clad metal plates. The company’s products include oilfield products, explosive metalworking equipment, and AMK welding equipment, …
  • Oge Energy Corp
    Oge Energy Corp - Strategy, SWOT and Corporate Finance Report Summary Oge Energy Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Brokk AB:企業の戦略的SWOT分析
    Brokk AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • SurModics Inc (SRDX):企業の財務・戦略的SWOT分析
    SurModics Inc (SRDX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Pacific Ethanol Inc (PEIX):企業の財務・戦略的SWOT分析
    Pacific Ethanol Inc (PEIX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Cosmo Pharmaceuticals NV (COPN)-医療機器分野:企業M&A・提携分析
    Summary Cosmo Pharmaceuticals NV (Cosmo) is a pharmaceutical company that develops drugs for the treatment of gastro-intestinal diseases. The company develops its pharmaceutical products based on its multi matrix (MMX) technology. Its proprietary clinical development pipeline intended for the treatm …
  • Impresa Pizzarotti & C. S.p.A.:企業の戦略・SWOT・財務情報
    Impresa Pizzarotti & C. S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Impresa Pizzarotti & C. S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • The Sherwin-Williams Company:企業の戦略・SWOT・財務分析
    The Sherwin-Williams Company - Strategy, SWOT and Corporate Finance Report Summary The Sherwin-Williams Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Cosmax Inc.:企業の戦略・SWOT・財務情報
    Cosmax Inc. - Strategy, SWOT and Corporate Finance Report Summary Cosmax Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆